dr. wakelee on first-line therapy for egfr-mutant lung cancer
Published 6 years ago • 201 plays • Length 1:16Download video MP4
Download video MP3
Similar videos
-
6:56
first-line therapy in the patient with egfr-mutant lung cancer
-
1:57
dr. wakelee on benefits of osimertinib in egfr-mutant nsclc treatment
-
1:29
dr. wakelee on available treatments following tumor progression in lung cancer
-
1:27
dr. wakelee discusses egfr tkis in lung cancer
-
1:05
dr. wakelee on recent advancements in egfr-mutant nsclc
-
2:03
dr. wakelee on rationale to explore osimertinib with concurrent chemotherapy in egfr-mutant nsclc
-
2:19
dr. wakelee on detection of egfr t790m mutation in nsclc
-
2:14
dr. yang on osimertinib as first-line therapy for egfr-positive nsclc
-
1:23
dr. wakelee on veristrat testing in non-small cell lung cancer
-
1:26
dr. wakelee on explaining adjuvant therapy benefits to patients
-
1:37
dr. yu on treatments for egfr-mutant lung cancer
-
5:02
egfr-mutant lung cancer: initial approach
-
1:35
dr. wakelee on unmet needs for immunotherapy in nsclc
-
1:36
dr. heather wakelee on what to do when resistance to egfr tkis emerges
-
1:13
dr. wakelee discusses the future of lung cancer adjuvant therapy
-
2:18
dr. wakelee on first trial to combine antiangiogenesis agents with immunotherapy in nsclc
-
58:47
15 years of advances in egfr mutant lung cancer
-
2:21
dr. wakelee on the rationale for immunotherapy in nsclc
-
1:35
dr. wakelee discusses maintenance therapy for patients with lung cancer